European commercial launch of first approved life-saving treatment...

Jazz Pharmaceuticals plc and Gentium S.p.A., a Jazz Pharmaceuticals company, have announced the commencement of the European commercial launch of Defitelioq , the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.[1] The ... (more)

http://ift.tt/1jzSu9b